{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T21:13:03Z","timestamp":1761513183595},"reference-count":34,"publisher":"Wiley","issue":"S4","license":[{"start":{"date-parts":[[2012,9,6]],"date-time":"2012-09-06T00:00:00Z","timestamp":1346889600000},"content-version":"vor","delay-in-days":6154,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Obesity Research"],"published-print":{"date-parts":[[1995,11]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>d Fenfluramine (dF) (15 mg twice daily) has been studied in controlled trials in human obesity. It has been shown to increase adherence to weight lowering programs, to double the number of patients losing 10 kg or more when compared with a fairly efficient placebo plus dietary counselling, and to prevent weight regain when continued over a 1 year period. Weight loss after 1 month and 4 months is likely to predict subsequent outcome. Also, significant improvement in metabolic risk factors and blood pressure were clearly demonstrated, even more markedly in some obesity\u2010associated diseases, when body weight is maintained at a lower level. Even moderate but sustained weight loss of some 10 % of starting weight or less has been confirmed to be of medical value. Tolerance and safety of dF can be considered acceptable, even if longer term follow\u2010up is clearly needed.<\/jats:p><jats:p>These studies support the concept that long\u2010term pharmacotherapy with this serotoninergic drug might help achieve better outcome in the management of many obese patients, particularly in preventing relapse. The long\u2010term managerial strategies to be developed for each patient might thus include dF together with dietary advice, behavioral modification and physical exercise, either simultaneously or sequentially.<\/jats:p>","DOI":"10.1002\/j.1550-8528.1995.tb00217.x","type":"journal-article","created":{"date-parts":[[2012,9,6]],"date-time":"2012-09-06T17:51:29Z","timestamp":1346953889000},"source":"Crossref","is-referenced-by-count":28,"title":["Clinical Studies with Dexfenfluramine: From Past to Future"],"prefix":"10.1002","volume":"3","author":[{"given":"Bernard","family":"Guy\u2010Grand","sequence":"first","affiliation":[]}],"member":"311","published-online":{"date-parts":[[2012,9,6]]},"reference":[{"key":"e_1_2_1_2_2","first-page":"251","article-title":"Influence of short\u2010term dexfenfluramine therapy on glucose and lipid metabolism in obese non diabetic patients","volume":"128","author":"Andersen PH","year":"1993","journal-title":"Acta Endocrinol (Copenh)."},{"key":"e_1_2_1_3_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00315204"},{"key":"e_1_2_1_4_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1749-6632.1987.tb36216.x"},{"key":"e_1_2_1_5_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-103-6-994"},{"key":"e_1_2_1_6_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.291.6492.379"},{"key":"e_1_2_1_7_2","first-page":"13","article-title":"Benefits of reducing revisited","volume":"60","author":"Blackburn GL","year":"1984","journal-title":"Postgrad Med J."},{"key":"e_1_2_1_8_2","first-page":"449","article-title":"Obesity: basic considerations and clinical approaches","volume":"18","author":"Bray GA.","year":"1989","journal-title":"Dis Mon."},{"key":"e_1_2_1_9_2","first-page":"199","article-title":"Dexfenfluramine reduces cardiovascular risk factors","volume":"18","author":"Bremer JM","year":"1994","journal-title":"Int J Obes."},{"key":"e_1_2_1_10_2","doi-asserted-by":"publisher","DOI":"10.1136\/hrt.70.6.537"},{"key":"e_1_2_1_11_2","doi-asserted-by":"crossref","first-page":"5035","DOI":"10.1093\/ajcn\/55.2.503s","article-title":"Economic cost of obesity","volume":"55","author":"Colditz CA.","year":"1992","journal-title":"Am J Clin Nutr."},{"issue":"1","key":"e_1_2_1_12_2","first-page":"S173","article-title":"Efficacy and safety of dexfenfluramine in obese patients","volume":"11","author":"Enzi G.","year":"1988","journal-title":"Clin Neuropharmacol."},{"key":"e_1_2_1_13_2","first-page":"91","article-title":"Prolonged use of a very low calorie diet in massively obese patients: safety, efficacy and additional benefit from dexfenfluramine","volume":"13","author":"Finer N.","year":"1989","journal-title":"Int J Obes."},{"key":"e_1_2_1_14_2","first-page":"1","article-title":"Beneficial health effects of modest weight loss","volume":"16","author":"Goldstein DJ.","year":"1992","journal-title":"Int J Obes."},{"key":"e_1_2_1_15_2","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1016\/S0002-8223(21)01364-X","article-title":"Why treatments for obesity don't last","volume":"91","author":"Goodrick GK","year":"1991","journal-title":"J Am Diet Assoc."},{"key":"e_1_2_1_16_2","first-page":"271","volume-title":"Body Weight Control: Physiology, Clinical Control and Prevention of Obesity","author":"G\u00f6testam KF","year":"1987"},{"key":"e_1_2_1_17_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1749-6632.1987.tb36222.x"},{"issue":"2","key":"e_1_2_1_18_2","first-page":"106","article-title":"Dexfenfluramine lowers blood pressure independently of weight loss: data from the INDEX study","volume":"18","author":"Guy\u2010Grand B.","year":"1994","journal-title":"Int J Obes."},{"issue":"2","key":"e_1_2_1_19_2","first-page":"48","article-title":"Effect of withdrawal of dexfenfluramine on body weight and food intake after a one year's administration","volume":"14","author":"Guy\u2010Grand B.","year":"1991","journal-title":"Int J Obes."},{"key":"e_1_2_1_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(89)91499-2"},{"key":"e_1_2_1_21_2","first-page":"311","volume-title":"Obesity in Europe 88","author":"Guy\u2010Grand B.","year":"1989"},{"key":"e_1_2_1_22_2","first-page":"280","volume-title":"Body Weight Control: The Physiology, Clinical Treatment and Prevention of Obesity","author":"Guy\u2010Grand B.","year":"1987"},{"key":"e_1_2_1_23_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00265922"},{"issue":"2","key":"e_1_2_1_24_2","first-page":"59","article-title":"Dexfenfluramine selectively reduces visceral and hepatic fat and improves insulin sensitivity","volume":"18","author":"Marks SJ","year":"1994","journal-title":"Int J Obes."},{"key":"e_1_2_1_25_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2796.1992.tb00560.x"},{"key":"e_1_2_1_26_2","first-page":"612","article-title":"A six months study of the effects of dexfenfluramine on partially successful dieters","volume":"47","author":"Noble RE.","year":"1990","journal-title":"Curr Ther Res."},{"key":"e_1_2_1_27_2","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.14.4.325"},{"issue":"1","key":"e_1_2_1_28_2","first-page":"17","article-title":"Effect of dexfenfluramine on insulin sensitivity in insulin treated type II B diabetic patients","volume":"16","author":"Schohenfeld\u2010Naor Y.","year":"1993","journal-title":"Int J Obes."},{"key":"e_1_2_1_29_2","doi-asserted-by":"publisher","DOI":"10.5694\/j.1326-5377.1993.tb121695.x"},{"key":"e_1_2_1_30_2","first-page":"A124","article-title":"Improvement of glycemic control and weight loss in type II diabetics after one year of dexfenfluramine treatment","volume":"33","author":"Tauber","year":"1990","journal-title":"Diabetologia."},{"issue":"2","key":"e_1_2_1_31_2","first-page":"39","article-title":"Treatment of obesity by very low calorie diet, behavior therapy, and their combination: a five year perspective","volume":"13","author":"Wadden TA","year":"1989","journal-title":"Int J Obes."},{"key":"e_1_2_1_32_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-5491.1992.tb01793.x"},{"key":"e_1_2_1_33_2","first-page":"261","article-title":"Outpatient treatments of obesity: a comparison of the methodology and clinical results","volume":"3","author":"Wing RR","year":"1979","journal-title":"Int J Obes."},{"key":"e_1_2_1_34_2","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.1991.00400070100012"},{"key":"e_1_2_1_35_2","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1992.74"}],"container-title":["Obesity Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fj.1550-8528.1995.tb00217.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/j.1550-8528.1995.tb00217.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,23]],"date-time":"2023-11-23T08:23:01Z","timestamp":1700727781000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/j.1550-8528.1995.tb00217.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1995,11]]},"references-count":34,"journal-issue":{"issue":"S4","published-print":{"date-parts":[[1995,11]]}},"alternative-id":["10.1002\/j.1550-8528.1995.tb00217.x"],"URL":"https:\/\/doi.org\/10.1002\/j.1550-8528.1995.tb00217.x","archive":["Portico"],"relation":{},"ISSN":["1071-7323","1550-8528"],"issn-type":[{"value":"1071-7323","type":"print"},{"value":"1550-8528","type":"electronic"}],"subject":[],"published":{"date-parts":[[1995,11]]}}}